Summary Background Concurrent with the Pfizer–BioNTech BNT162b2 COVID-19 vaccine
roll-out in Israel initiated on Dec 19, 2020, we assessed the early antibody responses and …

Background Despite high vaccine coverage and effectiveness, the incidence of symptomatic
infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

Background Previous infection with SARS-CoV-2 affects the immune response to the first
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …

Clinical trials and real-world evidence on COVID-19 vaccines have shown their
effectiveness against severe disease and death but the durability of protection remains …

Importance Randomized clinical trials have provided estimates of the effectiveness of the
BNT162b2 vaccine against symptomatic SARS-CoV-2 infection, but its effect on …

Background SARS-CoV-2 vaccines are an invaluable resource against COVID-19. Current
vaccine shortage makes it necessary to prioritize distribution to the most appropriate …

Background Vaccine-induced population immunity is a key global strategy to control
coronavirus disease 2019 (COVID-19). The rapid implementation and availability of several …

Background: The first goal of the study was to analyse the antibody titre 21 days after the first
dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second …

Objectives To assess the antibody response to BNT162b2 mRNA COVID-19 vaccine in a
cohort of health-care workers (HCW), comparing individuals with previous severe acute …

Importance Despite the high 3-dose vaccination rate among health care workers (HCWs) in
Israel, a high rate of SARS-CoV-2 breakthrough infections in this group was observed during …